newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra
Health

Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL)

Glenmark Pharmaceuticals Inc. USA launches Latanoprost Ophthalmic Solution

Bengaluru, February 14, 2025 – Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the launch1 of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL). Glenmark’s Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan®2 Ophthalmic Solution, 0.005% of Upjohn US 2 LLC.

According to IQVIATM sales data for the 12-month period ending December 2024, the Xalatan® Ophthalmic Solution, 0.005% market3 achieved annual sales of approximately $113.5 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of our 4th ophthalmic product, Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), growing our portfolio of products within the ophthalmic channel. This addition highlights our commitment to meeting market needs and providing quality solutions for our customers.”

Related posts

At Apex Superspeciality Hospitals, Dr. Vividh Makwana Sets Landmark Record with 582 Total Knee Replacements in One Year, Including 363 Robotic Surgeries

Newsmantra

The link between anxiety and testosterone discovered by Israeli Researchers

Newsmantra

Unlocking Vision Wellness: Allergan’s Media Conclave on World Sight Day Spotlights Eyecare’s Crucial Role in the Modern Workplace

Newsmantra

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More